RT Journal Article
T1 Hereditary angioedema due to C1 inhibitor deficiency: real-world experience from the Icatibant Outcome Survey in Spain
A1 Guilarte, Mar
A1 Sala-Cunill, Anna
A1 Luisa Baeza, Maria
A1 Cabanas, Rosario
A1 Dolores Hernandez, Maria
A1 Ibanez, Ethel
A1 Hernando de Larramendi, Carlos
A1 Lleonart, Ramon
A1 Lobera, Teofilo
A1 Marques, Luis
A1 de San Pedro, Blanca Saenz
A1 Botha, Jaco
A1 Andresen, Irmgard
A1 Caballero, Teresa
A1 IOS Study Grp, 
K1 Hereditary angioedema
K1 Registries
K1 Spain
K1 Bradykinin
K1 Bradykinin B-2 receptor antagonists
K1 Icatibant
K1 On-demand treatment
K1 Attacks
K1 Management
K1 Symptoms
AB Background The Icatibant Outcome Survey (IOS) is an international registry monitoring the use of icatibant, a bradykinin B-2 receptor antagonist indicated for the acute treatment of hereditary angioedema (HAE) attacks. Our goal was to assess disease characteristics and icatibant treatment outcomes in patients with HAE due to C1 inhibitor deficiency (HAE type 1 or 2 (HAE-1/2)) from Spain relative to other countries participating in IOS. Methods Descriptive retrospective analyses of data are reported from 10 centers in Spain vs 51 centers in 12 other participating countries (July 2009 to January 2019). Results No meaningful differences were identified between patients in Spain (n = 119) and patients across other countries (n = 907) regarding median age at symptom onset (15.0 vs 12.0 years) or diagnosis (22.3 vs 20.5 years). Overall HAE attack rates (total attacks/total years of follow-up) were 2.66 in Spain and 1.46 across other countries. Patients in Spain reported fewer severe/very severe HAE attacks before treatment (41.0% vs 45.9%; P
PB Bmc
SN 1710-1492
YR 2021
FD 2021-12-29
LK https://hdl.handle.net/10668/26598
UL https://hdl.handle.net/10668/26598
LA en
DS RISalud
RD Apr 17, 2025